AchromoPhage
AXP000240.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Originator
- University of Pittsburgh
- Sponsor
- University of Pittsburgh
Names
| Name | Type | Source |
|---|---|---|
| AchromoPhage | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Achromobacter bacteriophage (cocktail)
- Replication
- replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07275905 | Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection | Recruiting | Phase 1 | 2026-08-20 | 2028-01 | 12 | Achromobacter Infection; Cystic Fibrosis (CF) |
Recent changes
No changes recorded in its trials yet.
Notes
Achromobacter-targeting phage cocktail in a phase 1 pilot trial in people with cystic fibrosis and chronic Achromobacter lung infection (NCT07275905).
How to cite
AchromoPhage (AXP000240.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000240.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.